<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751348</url>
  </required_header>
  <id_info>
    <org_study_id>110876</org_study_id>
    <nct_id>NCT00751348</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136</brief_title>
  <official_title>Immunogenicity &amp; Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3b study is being conducted for the purpose of registration of the GSK208136
      vaccine in Korea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Seroconversion rates for measles, mumps, rubella and varicella</measure>
    <time_frame>approximately 42-56 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measles, mumps, rubella and varicella antibody titres</measure>
    <time_frame>42-56 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local symptoms (injection site redness, pain and swelling)</measure>
    <time_frame>within four days after vaccination (Day 0-3)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited general symptoms in terms of fever, rash, any sign of meningitis including febrile convulsion and parotitis</measure>
    <time_frame>within 43 days after each vaccination (Day 0-42)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited symptoms</measure>
    <time_frame>within 43 days after vaccination (Day 0-42)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>from the study vaccine dose up to study end</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <condition>Mumps</condition>
  <condition>Measles</condition>
  <condition>Measles-Mumps-Rubella-Varicella Vaccine</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PriorixTM</intervention_name>
    <description>Subcutaneous administration in left upper arm</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VarilrixTM</intervention_name>
    <description>Subcutaneous administration in right upper arm</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' vaccine 208136</intervention_name>
    <description>Subcutaneous injection in left upper arm</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  A male or female between, and including 11 and 24 months of age, at the time of the
             vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use
             during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the vaccine dose.

          -  Administration of immunoglobulins and/or any blood products during the six months
             before entering the study or planned administration during the study period.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol within 30 days prior to until 42 days after the study vaccine dose with the
             exception of inactivated vaccines such as pneumococcal, Haemophilus influenzae type b
             conjugate vaccines, inactivated influenza, hepatitis A or B vaccine or
             diphtheria/tetanus-containing vaccines which can be administered up to eight days
             before the study vaccine dose.

          -  Previous vaccination against measles, mumps, rubella and/or varicella.

          -  History of measles, mumps, rubella and/or varicella/zoster diseases.

          -  Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to
             study start.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s), including systemic hypersensitivity to neomycin.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment.

          -  Rectal temperature ≥ 38°C or axillary temperature ≥ 37.5°C at the time of
             vaccination.

          -  Residence in the same household as a high risk person e.g.:

               -  New-born infants (0-4 weeks of age)

               -  Pregnant women who have a negative history of chickenpox

               -  Persons with known immunodeficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>GyeongSangNam-do</city>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iksan</city>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju Jeonbuk</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uijeongbu, Kyonggi-do</city>
        <zip>480-130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wonju-si Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>January 12, 2012</lastchanged_date>
  <firstreceived_date>September 10, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>second year of life</keyword>
  <keyword>one-dose schedule</keyword>
  <keyword>varicella</keyword>
  <keyword>rubella</keyword>
  <keyword>measles</keyword>
  <keyword>mumps</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Mumps</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
